Abstract
During the last year, many papers in scientific journals have commented on the possible removal of the ban on direct-to-consumer advertising (DTCA) of prescription drugs by the European Parliament [1–3]. The promotion of prescription drugs directly to the public is currently allowed only in the USA and New Zealand. The risks related to this decision are brought into focus, especially if we consider the situation in the USA, where DTCA has been permitted since 1997.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
